GlaxoSmithKline
SPOTLIGHT: Pfizer, GSK hike prices to boost sales
Pfizer and GlaxoSmithKline boosted wholesale drug prices by about 9 percent on their 10 best-sellers last year. These price increases come as both companies brace for generic competition for... Read more...
ALSO NOTED: Detroit medical center cuts doctor pay for indigent care; U of Iowa plans $700M+ expansion campaign; and much more.
> The Detroit Medical Center has made plans to cut payments to Wayne State University School of Medicine by $12 million a year, contending that WSU pays too much to doctors who treat indigent... Read more...
ALSO NOTED: HHS budgets $150M to promote EMR use by small med groups; Glaxo wins Paxil suicide case; and much more...
> HHS is moving ahead with its $150 million incentive plan designed to promote the use of electronic medical records in smaller medical groups. Read more...
Avandia gets black-box warning
The following isn't a big shock, but it's still an important development--blockbuster diabetes drug Avandia will now carry a black-box warning. In addition to posting the warning on Avandia... Read more...
VA removes Avandia from its formulary
VA dealt a body blow to type 2 diabetes drug Avandia this week, deciding that while it would continue to make the drug available to existing users, officials would no longer allow it to be prescribed... Read more...
FDA, drug makers to study drug side-effects
A group of the world's biggest drug makers have come together with the FDA to look into the reasons why a small subset of patients have medication severe side effects. To attack the problem, the... Read more...
Avandia slammed by more studies
Two more studies have come out which raise further questions about the safety of diabetes drug Avandia. The first of the two studies, which were published in The Journal of the American Medical... Read more...
FDA panel votes to keep Avandia on the market
Despite new data suggesting it poses health risks, an FDA advisory panel voted yesterday to keep diabetes drug Avandia on the market. Several members of the panel argued studies citing its risks... Read more...
If costly drugs don't work, prices go down
Increasingly, the mind-blowing cost of biologic drugs is straining the healthcare system, with some hitting unheard of levels of $100,000 per year or more. Not sure how to cope with the cost of these... Read more...
Glaxo: Avandia critic should pay for stock drop
A researcher and early critic of Avandia told Congress yesterday that a GlaxoSmithKline executive threatened him with dire financial consequences when he raised concerns about the drug. Dr. John Buse, who testified before a House panel yesterday, told investigators that Glaxo executive Dr. Tadataka Yamada suggested that he should be responsible for the $4 billion drop in stock value Glaxo suffered after Avandia safety concerns came to light. In light of similar findings by …
... Read more...